Συγγραφείς:
Justet, A.
Klay, D.
Porcher, R.
Cottin, V.
Ahmad, K.
Molina, M.M.
Nunes, H.
Reynaud-Gaubert, M.
Naccache, J.M.
Manali, E.
Froidure, A.
Jouneau, S.
Wemeau, L.
Andrejak, C.
Gondouin, A.
Hirschi, S.
Blanchard, E.
Bondue1, B.
Bonniaud, P.
Tromeur, C.
Prévot, G.
Marchand-Adam, S.
Funke-Chambour, M.
Gamez, A.S.
Ba, I.
Papiris, S.
Grutters, J.
Crestani, B.
Van Moorsel, C.
Kannengiesser, C.
Λέξεις-κλειδιά:
dyskerin; nintedanib; pirfenidone; telomerase reverse transcriptase; dipyrone; indole derivative; nintedanib; pirfenidone, age; antifibrotic therapy; Belgium; confounding variable; demography; diffusing capacity for carbon monoxide; disease exacerbation; disease severity; drug efficacy; drug safety; drug withdrawal; fibrosing alveolitis; follow up; forced vital capacity; gastrointestinal disease; gene; gene mutation; genetic variability; Greece; human; hypertransaminasemia; Letter; lung fibrosis; lung function test; lung transplantation; multidisciplinary team; Netherlands; PARN gene; people by smoking status; prediction; respiratory failure; RTEL1 gene; self report; skin manifestation; Spain; Switzerland; telomere; TERC gene; TERT gene; treatment withdrawal; fibrosing alveolitis; genetics; mutation; treatment outcome, Humans; Idiopathic Pulmonary Fibrosis; Indoles; Mutation; Pyridones; Telomere; Treatment Outcome
